July 15, 2004Journal of Clinical Oncology
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
Authors
Discussion
Loading...
Member takes
Implication
Key Points
Key points are not available for this paper at this time.
Cite This Study
Shepherd et al. (2004) studied this question.